Siegfried Holding AG

SWX:SFZN Stock Report

Market Cap: CHF 4.7b

Siegfried Holding Valuation

Is SFZN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SFZN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SFZN (CHF1096) is trading above our estimate of fair value (CHF498.59)

Significantly Below Fair Value: SFZN is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SFZN?

Key metric: As SFZN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SFZN. This is calculated by dividing SFZN's market cap by their current earnings.
What is SFZN's PE Ratio?
PE Ratio36.5x
EarningsCHF 128.86m
Market CapCHF 4.70b

Price to Earnings Ratio vs Peers

How does SFZN's PE Ratio compare to its peers?

The above table shows the PE ratio for SFZN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average46.3x
BANB Bachem Holding
45.2x17.9%CHF 5.1b
TECN Tecan Group
26.4x14.2%CHF 2.7b
SKAN SKAN Group
49.5x18.7%CHF 1.6b
LONN Lonza Group
64x23.9%CHF 36.7b
SFZN Siegfried Holding
36.5x13.6%CHF 4.7b

Price-To-Earnings vs Peers: SFZN is good value based on its Price-To-Earnings Ratio (36.5x) compared to the peer average (46.3x).

Price to Earnings Ratio vs Industry

How does SFZN's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
SFZN 36.5xIndustry Avg. 36.9xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SFZN is good value based on its Price-To-Earnings Ratio (36.5x) compared to the European Life Sciences industry average (37.1x).

Price to Earnings Ratio vs Fair Ratio

What is SFZN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SFZN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio36.5x
Fair PE Ratio20.6x

Price-To-Earnings vs Fair Ratio: SFZN is expensive based on its Price-To-Earnings Ratio (36.5x) compared to the estimated Fair Price-To-Earnings Ratio (20.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SFZN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 1,096.00
CHF 1,187.67
+8.4%
11.6%CHF 1,500.00CHF 990.00n/a12
Nov ’25CHF 1,150.00
CHF 1,187.67
+3.3%
11.6%CHF 1,500.00CHF 990.00n/a12
Oct ’25CHF 1,144.00
CHF 1,162.75
+1.6%
11.8%CHF 1,500.00CHF 990.00n/a12
Sep ’25CHF 1,118.00
CHF 1,075.15
-3.8%
7.8%CHF 1,188.00CHF 900.00n/a13
Aug ’25CHF 1,024.00
CHF 1,041.00
+1.7%
8.9%CHF 1,188.00CHF 880.00n/a12
Jul ’25CHF 944.00
CHF 1,015.90
+7.6%
7.4%CHF 1,125.00CHF 880.00n/a10
Jun ’25CHF 899.00
CHF 1,015.90
+13.0%
7.4%CHF 1,125.00CHF 880.00n/a10
May ’25CHF 882.00
CHF 1,015.90
+15.2%
7.4%CHF 1,125.00CHF 880.00n/a10
Apr ’25CHF 921.00
CHF 1,005.36
+9.2%
7.8%CHF 1,125.00CHF 880.00n/a11
Mar ’25CHF 905.00
CHF 964.55
+6.6%
7.2%CHF 1,050.00CHF 820.00n/a11
Feb ’25CHF 846.00
CHF 911.60
+7.8%
8.4%CHF 1,000.00CHF 800.00n/a10
Jan ’25CHF 859.50
CHF 891.22
+3.7%
7.5%CHF 990.00CHF 800.00n/a9
Dec ’24CHF 782.50
CHF 881.88
+12.7%
7.4%CHF 990.00CHF 800.00n/a8
Nov ’24CHF 714.50
CHF 881.88
+23.4%
7.4%CHF 990.00CHF 800.00CHF 1,150.008
Oct ’24CHF 784.50
CHF 871.88
+11.1%
7.8%CHF 990.00CHF 800.00CHF 1,144.008
Sep ’24CHF 789.00
CHF 860.56
+9.1%
11.8%CHF 990.00CHF 640.00CHF 1,118.009
Aug ’24CHF 769.50
CHF 817.50
+6.2%
11.9%CHF 945.00CHF 640.00CHF 1,024.008
Jul ’24CHF 739.00
CHF 813.13
+10.0%
12.0%CHF 945.00CHF 640.00CHF 944.008
Jun ’24CHF 734.00
CHF 815.00
+11.0%
12.7%CHF 945.00CHF 640.00CHF 899.007
May ’24CHF 686.50
CHF 805.00
+17.3%
12.2%CHF 945.00CHF 640.00CHF 882.007
Apr ’24CHF 671.50
CHF 819.29
+22.0%
13.0%CHF 945.00CHF 640.00CHF 921.007
Mar ’24CHF 666.00
CHF 838.88
+26.0%
13.4%CHF 971.00CHF 640.00CHF 905.008
Feb ’24CHF 674.50
CHF 869.50
+28.9%
9.3%CHF 971.00CHF 700.00CHF 846.008
Jan ’24CHF 613.50
CHF 869.50
+41.7%
9.3%CHF 971.00CHF 700.00CHF 859.508
Dec ’23CHF 645.50
CHF 869.50
+34.7%
9.3%CHF 971.00CHF 700.00CHF 782.508
Nov ’23CHF 605.50
CHF 904.19
+49.3%
6.7%CHF 995.50CHF 825.00CHF 714.508

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Gerresheimer

€2.5b

Manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally.

GXI

€75.60

7D

0%

1Y

0%

Roche Holding

CHF 203.6b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

ROG

CHF 253.50

7D

-4.5%

1Y

6.9%

Bristol-Myers Squibb

US$100.3b

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

BMY

US$54.24

7D

0%

1Y

0%